Mohs micrographic surgery is a technique used to excise skin tumors based on comprehensive surgical mapping, in which the surgeon removes the tumor, followed by a complete histological evaluation of the tumor's margins. The correlation of the presence of a tumor in histological examinations and its precise location on the surgical map result in a complete removal of the tumor with maximum normal tissue preservation. The present article seeks to provide general practitioners and healthcare specialists with guidelines regarding recommendations for Mohs micrographic surgery to treat skin tumors, based on the most reliable evidence available in medical literature on the subject. This bibliographic review of scientific articles in this line of research was conducted based on data collected from MEDLINE/PubMed. The search strategy used in this study was based on structured questions in the Patient, Intervention, Control, and Outcome (PICO) format. MeSH terms were used as descriptors. The indications of this technique are related to recurrence, histology, size, definition of tumor margins, and location of tumors. These guidelines attempt to establish the indications of Mohs surgery for different types of skin tumors.
INTRODUCTION
Mohs Micrographic Surgery (MMS) is a technique used to excise skin lesions characterized by surgical mapping, in which the surgeon removes the lesion, followed by a complete histological evaluation of the tumor margins. The correlation of a tumor's detection in histological exams and its precise location on the surgical map are essential for complete tumor removal and normal tissue preservation.
MMS begins with tumor removal, followed by the delineation of a margin, varying from 2 to 5 mm, according to the lesion's histological type and location.
Next, a thin layer from the tumor bed is removed, and this excised tissue is then cut into small fragments, designing a map where these fragments are numbered, leading to a precise location of these in the tumor bed. The fragments are frozen and cut in a cryostat, and the slides are stained with hematoxylin-eosin (HE) or toluidine blue. The surgeon trained in this technique, reads them under a microscope. Once tumor has been detected in a fragment, it is then precisely identified on the surgical map, and removed in both a well-guided and economical manner, with the preservation of healthy tissues. (D) [1] [2] [3] [4] Exeresis of the tumor ends when all of its margins are deemed to be negative. At this point, reconstruction begins, utilizing the same techniques used in conventional excisional surgery (CES) (Figure 1 ).
To remove the tumors that invade deep tissues, such as in the periorbitary regions or in the sinuses, the use of general anesthesia may be necessary. In these situations, the treatment must be executed by a multidisciplinary team, which can include head and neck surgeons, plastic surgeons, and otorhinolaryngologists, among others.
It is important to highlight that the examination of the
Is MMS recommended for the recurrent or incomplete excised basal cell carcinoma (BCC)?
Among recurrent tumors, there are a high percentage of lesions with aggressive histopathologic patterns (65%). These lesions are characterized by a significant SCE, which is higher than that found in non-aggressive tumors. (B) 5 In a study of subclinical extension of Basal BCC located in the nose, it was found that recurrent lesions presented a 3.2 fold greater subclinical extension when compared to primary lesions. (D) 6 A study that evaluates the recurrence rate of different therapeutic modalities over the short term (<5 years), for previously treated BCC, found 19.1% for Non-Mohs modalities (surgery, radiotherapy, curettage, and cryotherapy), compared to 5.2% for tumors treated with MMS. Over the long term (>5 years), excluding cryotherapy, the recurrence rates were of 19.9%, versus 5.6% for MM (D) 7 In a report of 267 recurrent BCC cases, where MSS was reported, 95.6% of the patients were cured within a 5-year follow-up period. (D) 8 
Recommendation
For recurrent BCC, the presence of a significant SCE makes it difficult to define the limits of the lesion, resulting in an incomplete removal of the tumors through conventional techniques, which renders a high index of recurrent tumors. Available studies have shown better cure rates when MMS is applied.
In BCCs with aggressive biological behavior, is MMS a good option?
High-risk BCCs are defined as tumors that present a greater risk of recurrence. These lesions histological pattern are sclerodermiform, infiltrative, micronodular, or metatypical, also called basosquamous. This last type presents also a higher risk of metastasis.
In a study conducted with 1,131 patients submitted to The comparison among 69 micronodular and 60 nodular BCCs submitted to MMS, showed that the SCE, (p<0.001), the depth, and the number of stages were greater in micronodular, when com- recurrence rates. Available evidence shows that through a study of the total extension of the tumor margins, the MMS technique, allows a complete excision of these tumors, leading to higher cure rates.
Is the size a determining factor in recommending mms?
In a study conducted with 1,131 tumors submitted to MMS, it was found that lesions with initial dimensions above 10mm presented a significantly higher SCE, indicating that for their complete removal there were a larger number of stages, as compared to small tumors, with a size of up to 5mm. (D) 6 In 100 patients treated with MMS, the author found that 65% of the small tumors (<2cm), were removed within one stage, compared to only 30% among the larger lesions (>2cm) (p<0.05).
This finding is in accordance with a concept reported in the litera- BCCs located on the nose, eyebrows, and ears present greater tendency to invade deeper planes, which results in higher recurrence.
Hence, their excision can cause worse esthetic and functional sequel.
The CES used to treat BCC is based on the creation of a safety margin. However, due to the irregular and extensive subclinical growth in these locations, the rates of recurrence due to incomplete excision is high, as can be seen in the studies cited below.
In one study on percentage of incomplete excisions at a Plastic surgery center there were 1.214 BCCs of which 1,129 (93%)
were primary and 56 (4.6%) were recurrent tumors. Incomplete excision was higher for the lesions located on the head (14.5%, with p<0.005), as compared to other regions (7.0 to 8.5%). On that location the incomplete excision rates was as follows: on epicanthus The perineural invasion, which occurs in approximately 2.5-14% of the SCC cases (B)(C), presents one of the worst prognoses for the host, given that it is correlated to a high rate of recurrence (28.6% vs 13.6%) and metastasis (32.8% vs 9.2%) (B), especially when it is located in the head and neck region. (B) 19, 20, 24, 25 When conventional surgery is applied, these tumors present a rate of recurrence of up to 47.2%. By contrast, the recurrence of these cases, when the patient undergoes MMS, varies from 0-8%.
(D)(B)(C) [23] [24] [25] One Australian study that evaluated the cases of periocular SCC found three cases with perineural invasion that were submitted to MMS, while none presented any sign of recurrence after 4, 5, and 6 years of follow-up, respectively. (B)
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Recommendation
The MMS seems to be the better therapeutic option to treat SCCs that present perineural invasion, when compared to conventional surgery, as they provide lower rates of recurrence. In 58 cases of DFSP, the extension of tumor invasion was calculated through a study of the margins performed using freezing cuts used in MMS, it was observed that 15.5% of the tumors would have been incompletely excised if a 3 cm surgical margin had been used (C) 38 One retrospective study, comparing 28 patients submitted to excision with wide margins and 20 patients submitted to MMS reported the presence of a compromised margin in 21% of the patients submitted to excision with wide margins and 0% in the patients submitted to MMS (P=0.01), after re-intervention in the patients with compromised margins, the rate of recurrence was of 3.6%, as compared to 0% in the MMS group (P=1.0), considering a follow-up period of less than four years. (B) 39 Four non-controlled comparative studies showed rates of recurrence of 0 to 6.6% in the group treated with MMS and 0% to 13.2% in the group treated by excision with wide margins. (B) 40 
The recommendation for the use of MMS to treat DFSP is justified based on available evidence that suggests a greater risk of recurrence in patients submitted to this type of surgery. The explanation for the superiority of the MMS technique is due to its method, which allows one to better identify the subclinical extension of these tumors through a detailed mapping of the surgical margins.
DFSP is a soft parts sarcoma with a local invasive behavior and a low risk of metastasis. To date, no randomized and controlled studies exist that compare treatments performed using MMS with wide margin surgical excisions.q
